우유 생리활성 물질의 임상적 적용 = Clinical Applications of Bioactive Milk Components: A Review

다국어 초록 (Multilingual Abstract)

Milk contains essential nutrients and functional compounds, such as calcium, fat-soluble vitamins A, D, E, and K, carotenoids, bioactive peptides, and sphingolipids. The bioactive molecules from milk are not expensive and have an added advantage of being derived from food. Therefore, they are more stable and have a broader spectrum than that of other chemicals. Bioactive milk components are useful for treating non-digestive tract disorders, such as cancer, cognitive decline, and hypertension. However, the clinical application of certain breast milk ingredients is limited due to the lack of a large-scale production technology. Once the scaled-up production of lactoferrin became possible, clinical applications were devised and evaluated. Similarly, human alpha-lactalbumin made lethal to tumor cells (HAMLET) can be produced on a large scale as a recombinant protein in microorganisms or in transgenic cattle using suitable separation systems. HAMLET can be used to treat human skin papilloma and cancer. Studies on breast milk that explored the clinical applications of the bioactive components of breast milk have spurred the development of translational medicine and breast milk-derived therapeutics. Some breast- milk derived therapeutic agents are already available to clinicians. Many components of breast milk have shown efficacy in pre-clinical studies and have valid clinical evaluations.

참고문헌 (Reference)

1 Sun X, "“Ironsaturated”bovine lactoferrin improves the chemotherapeutic effects of tamoxifen in the treatment of basal-like breast cancer in mice" 12 : 591-, 2012

2 Parente F, "Treatment of Helicobacter pylori infection using a novel antiadhesion compound (3’sialyllactose sodium salt). A double blind, placebo-controlled clinical study" 8 : 252-256, 2003

3 Terrazas LI, "The schistosome oligosaccharide lacto-N-neotetraose expands Gr1(+) cells that secrete anti-inflammatory cytokines and inhibit proliferation of naive CD4(+) cells: a potential mechanism for immune polarization in helminth infections" 167 : 5294-5303, 2001

4 Nanthakumar N, "The mechanism of excessive intestinal inflammation in necrotizing enterocolitis: an immature innate immune response" 6 : e17776-, 2011

5 Jantscher-Krenn E, "The human milk oligosaccharide disialyllacto-N-tetraose prevents necrotising enterocolitis in neonatal rats" 61 : 1417-1425, 2012

6 Vitetta L, "The clinical efficacy of a bovine lactoferrin/whey protein Ig-rich fraction (Lf/IgF) for the common cold: a double blind randomized study" 21 : 164-171, 2013

7 Mossberg AK, "Structure and function of human α-lactalbumin made lethal to tumor cells (HAMLET)-type complexes" 277 : 4614-4625, 2010

8 Patwardhan GA, "Sphingolipids and expression regulation of genes in cancer" 50 : 104-114, 2011

9 Bode L, "Recent advances on structure, metabolism, and function of human milk oligosaccharides" 136 : 2127-2130, 2006

10 Ochoa TJ, "Randomized double-blind controlled trial of bovine lactoferrin for prevention of diarrhea in children" 162 : 349-356, 2013

11 Otto W, "Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli in volunteers" 46 : 862-868, 2011

12 Russo E, "Protective activity of α-lactoalbumin (ALAC), a whey protein rich in tryptophan, in rodent models of epileptogenesis" 226 : 282-288, 2012

13 Newburg DS, "Protection of the neonate by the innate immune system of developing gut and of human milk" 61 : 2-8, 2007

14 Citraro R, "Preclinical activity profile of α-lactoalbumin, a whey protein rich in tryptophan, in rodent models of seizures and epilepsy" 95 : 60-69, 2011

15 Rosqvist F, "Potential role of milk fat globule membrane in modulating plasma lipoproteins, gene expression, and cholesterol metabolism in humans: a randomized study" 102 : 20-30, 2015

16 Crane JK, "Oligosaccharides from human milk block binding and activity of the Escherichia coli heat-stable enterotoxin (STa) in T84intestinal cells" 124 : 2358-2364, 1994

17 Thompson AM, "Necrotizing enterocolitis in newborns: pathogenesis, prevention and management" 68 : 1227-1238, 2008

18 Zanabria R, "Milk fat globule membrane isolate induces apoptosis in HT-29 human colon cancer cells" 4 : 222-230, 2013

19 Brock JH, "Lactoferrin: 50 years on" 90 : 245-251, 2012

20 Edde L, "Lactoferrin protects neonatal rats from gut-related systemic infection" 281 : G1140-G1150, 2001

21 Laffan AM, "Lactoferrin for the prevention of post-antibiotic diarrhoea" 29 : 547-551, 2011

22 Atochina O, "LNFPIII/LeX-stimulated macrophages activate natural killer cells via CD40-CD40L interaction" 12 : 1041-1049, 2005

23 Li J, "Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer" 6 : 20984-, 2016

24 Bode L, "Inhibition of monocyte, lymphocyte, and neutrophil adhesion to endothelial cells by human milk oligosaccharides" 92 : 1402-1410, 2004

25 Riehl TE, "Hyaluronic acid is radioprotective in the intestine through a TLR4 and COX-2-mediated mechanism" 302 : G309-G316, 2012

26 Fischer W, "Human α-lactalbumin made lethal to tumor cells (HAMLET) kills human glioblastoma cells in brain xenografts by an apoptosis-like mechanism and prolongs survival" 64 : 2105-2112, 2004

27 Eiwegger T, "Human milk-derived oligosaccharides and plant-derived oligosaccharides stimulate cytokine production of cord blood T-cells in vitro" 56 : 536-540, 2004

28 Bode L, "Human milk oligosaccharides: every baby needs a sugar mama" 22 : 1147-1162, 2012

29 Bode L, "Human milk oligosaccharides reduce platelet neutrophil complex formation leading to a decrease in neutrophil 2 integrin expression" 76 : 820-826, 2004

30 Coppa GV, "Human milk oligosaccharides inhibit the adhesion to Caco-2 cells of diarrheal pathogens:Escherichia coli, Vibrio cholerae, and Salmonella fyris" 59 : 377-382, 2006

31 Engfer MB, "Human milk oligosaccharides are resistant to enzymatic hydrolysis in the upper gastrointestinal tract" 71 : 1589-1596, 2000

32 de Bortoli N, "Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics" 102 : 951-956, 2007

33 Duringer C, "HAMLET interacts with histones and chromatin in tumor cell nuclei" 278 : 42131-42135, 2003

34 Guo Z, "Enzymatic modification of phospholipids for functional applications and human nutrition" 23 : 203-259, 2005

35 Zhang Y, "Efficient separation of homologous α-lactalbumin from transgenic bovine milk using optimized hydrophobic interaction chromatography" 1217 : 3668-3673, 2010

36 Zavaleta N, "Efficacy of rice-based oral rehydration solution containing recombinant human lactoferrin and lysozyme in Peruvian children with acute diarrhea" 44 : 258-264, 2007

37 Tawfeek HI, "Efficacy of an infant formula containing anti-Escherichia coli colostral antibodies from hyperimmunized cows in preventing diarrhea in infants and children: a field trial" 7 : 120-128, 2003

38 Kozu T, "Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial" 2 : 975-983, 2009

39 Kaito M, "Effect of lactoferrin in patients with chronic hepatitis C: combination therapy with interferon and ribavirin" 22 : 1894-1897, 2007

40 Bollyky PL, "ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors" 108 : 7938-7943, 2011

41 Snow DR, "Dietary milk fat globule membrane reduces the incidence of aberrant crypt foci in Fischer-344 rats" 58 : 2157-2163, 2010

42 Castro-Gomez MP, "Comprehensive study of the lipid classes of krill oil by fractionation and identification of triacylglycerols, diacylglycerols, and phospholipid molecular species by using UPLC/QToF-MS" 8 : 2568-2580, 2015

43 Hill DR, "Clinical applications of bioactive milk components" 73 : 463-476, 2015

44 Gustafsson L, "Changes in proteasome structure and function caused by HAMLET in tumor cells" 4 : e5229-, 2009

45 Klement E, "Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis" 80 : 1342-1352, 2004

46 Manzoni P, "Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birthweight neonates: a randomized trial" 302 : 1421-1428, 2009

47 Manzoni P, "Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial" 129 : 116-123, 2012

48 Tung YT, "Bovine lactoferrin inhibits lung cancer growth through suppression of both inflammation and expression of vascular endothelial growth factor" 96 : 2095-2106, 2013

49 Mossberg AK, "Bladder cancers respond to intravesical instillation of HAMLET (human α-lactalbumin made lethal to tumor cells)" 121 : 1352-1359, 2007

50 Frey H, "Biological interplay between proteoglycans and their innate immune receptors in inflammation" 280 : 2165-2179, 2013

51 Hakansson A, "Apoptosis induced by a human milk protein" 92 : 8064-8068, 1995

52 Berlutti F, "Antiviral properties of lactoferrin: a natural immunity molecule" 16 : 6992-7018, 2011

53 Digumarti R, "A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer" 6 : 1098-1103, 2011

54 Guntupalli K, "A phase 2randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis" 41 : 706-716, 2013

55 King JC Jr, "A double-blind, placebo-controlled, pilot study of bovine lactoferrin supplementation in bottle-fed infants" 44 : 245-251, 2007